Uncategorized - Excalibur - Randomized Controlled Trial

May 2023: SLV/REK approved the extension of the Excalibur 2 trial ensuring continued inclusion also following the first analysis at 45 patients

May 2023: SLV/REK approved the extension of the Excalibur 2 trial ensuring continued inclusion also following the first analysis at 45 patientsJohn Brataas2023-09-05T08:20:41+00:00

April 2023: SLV/REK approved the 2c-stratum

April 2023: SLV/REK approved the 2c-stratumJohn Brataas2023-09-05T08:19:57+00:00

New supplier of floxuridine

From July -22 Cerona Therapeutics will supply floxuridine through Cardinal Health Specialty Pharmaceutical Services (Cardinal SPS). [...]

New supplier of floxuridineJohn Brataas2022-08-01T10:05:45+00:00

Updated information for ward and local hospitals has been posted on the archive

Download

Updated information for ward and local hospitals has been posted on the archiveJohn Brataas2022-06-22T20:42:58+00:00

MRI compatibility

Tricumed have applied for renewed MRI-compatibility for the pump Tricumed 2000V with expected approval august [...]

MRI compatibilityJohn Brataas2022-06-07T09:53:23+00:00

Status of exCalibur 1, 2 and 3
Gallery
Status of exCalibur 1, 2 and 3

Uncategorized

Status of exCalibur 1, 2 and 3

EXCALIBUR 1 and EXCALIBUR2 are steadily recruiting patients aiming to be fully included Q4 2023. [...]

Status of exCalibur 1, 2 and 3John Brataas2022-05-24T20:12:03+00:00